表紙
市場調查報告書

CountryFocus:新加坡的醫療·規定·醫療費給付制度狀況

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

出版商 GlobalData 商品編碼 321243
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
CountryFocus:新加坡的醫療·規定·醫療費給付制度狀況 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore
出版日期: 2020年04月30日內容資訊: 英文 140 Pages
簡介

新加坡的人口由於平均壽命的改善等影響,2008年為480萬人,到2013年持續增加到540萬人。各個因素加起來,醫藥品市場也從2008年為4億8900萬美金,持續增加到2013年的7億6100萬美金,這段期間以年平均成長率(CAGR)9.3%這個擴大趨勢持續成長。此外,推計到2014年市場規模為7億7600萬美金,2020年將達到8億7300萬美金,2014∼2020年的CAGR(年平均成長率)為2.0%。同時,醫療技術部門的生產額在2011年達到43億新幣(34億美金),到2015年預測將更進一步擴大到50億新幣(40億美金)的規模。政府積極的支援政策及大學熱烈地研究活動,有助於醫療相關市場的正向成長。

本報告提供新加坡的醫療相關市場趨勢,及醫療費給付制度和其他相關法規·制度的分析,提供醫藥品產業·醫療設備產業的整體結構與趨勢,醫療費給付制度及其週邊的保險市場趨勢,醫療法規當局結構和各種法規概要,彙整新加坡經濟·社會相關宏觀指標(醫療基礎設施等),今後的市場機會與課題的資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 醫藥品·醫療設備市場概要

  • 醫藥品市場
    • 市場概要
    • 醫藥品的進出口
    • 供給流通管道
    • 市場分類
    • 主要的疾病領域
    • 主要參與企業
  • 醫療設備市場
    • 市場概要
  • 市場推動因素與阻礙
    • 推動因素
    • 進入障礙

第4章 市場進入

  • 醫療費給付·保險費支付者狀況
    • 醫療制度概要
    • 醫療費給付流程
    • 保險經營者概要
    • 患者負擔佔醫療費用支出的比率
    • 醫療服務的價格趨勢
    • 藥價政策
  • 法規情形
    • 法規當局概要
    • 醫藥品的市售核准過程
    • 新醫療設備的認證過程
    • 醫療設備新產品的認證過程
    • 進出口
    • 知識產權
    • 臨床實驗的相關法規
    • 醫藥品的廣告相關法規
    • 藥局的相關法規
    • 標籤·包裝相關法規

第5章 各國分析

  • 政治環境
    • 政治結構
    • 目前政治環境相關分析
    • 醫療相關政策的配合措施
  • 經濟形勢
  • 經濟指標
    • 國內生產總值(GDP)
    • 國民所得毛額
    • 通貨膨脹
    • 匯率
    • 海外直接投資
    • 外匯儲備金
    • 貿易收支
    • 政府結構平衡
    • 國債發行總額
    • 主要產業
  • 人口統計
    • 人口
    • 教育及識字率
    • 工作情形
    • 疾病負擔
  • 醫療基礎設施
    • 醫療設備
    • 醫療參數
    • 環境衛生
    • 醫療人力資源
  • 醫療費
    • 概要
    • 官方/民間部門的佔有率
    • 醫療費用支出的主要的內容
    • 醫藥品的研究開發的支出額
  • 產業團體
  • 展覽會

第6章 市場機會及課題

  • 市場機會
  • 課題

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC0074CHR

GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

Singapore's pharmaceutical market value in terms of US dollars was worth $0.7B in 2012, which increased at a CAGR of 7.4% to $1.0B in 2017. The increasing pharmaceutical market value is attributed to high life expectancy, expansion of healthcare system, developed medical infrastructure, improved patient access, and an increasing number of foreign pharmaceutical companies with a regional headquarters. Singapore's medical devices market was valued at $2.55B in 2016, and was estimated to be $2.50B in 2019. The rapidly aging population drives demand for innovative medical technologies and therapeutic devices.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Roche, Novartis, Merck, GlaxoSmithKline, and Haw Par
  • Profiles and SWOT analyses of the major players in the medical device market: Medtronic, Becton Dickinson, Baxter International, Zimmer Biomet, and Edwards Lifesciences
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country's healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to -

  • Develop business strategies by understanding the trends shaping and driving Singapore's healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Singapore's healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

  • 1.1 List of Figures
  • 1.2 List of Tables

2 Executive Summary

  • 2.1 Executive Summary - Overview
  • 2.2 Key Highlights
  • 2.3 Key Highlights: Healthcare Start-Ups in Singapore
  • 2.4 Key Events: Singapore Healthcare History, 2002-2020
  • 2.5 Key Events: Singapore Pharmaceutical Market
  • 2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020
  • 2.7 Key Events: Mergers and Acquisitions
  • 2.8 Country Profile, Singapore, 2019

3 Overview of Pharmaceutical Market

  • 3.1 Pharmaceutical Market - Overview
  • 3.2 Pharmaceutical Market - Exports
  • 3.3 Pharmaceutical Market - Imports
  • 3.4 Pharmaceutical Market - Supply Channels, Singapore
  • 3.5 Pharmaceutical Market - Market Segments
  • 3.6 COVID-19 Epidemiology, Singapore
  • 3.7 COVID-19 Impact and Developments in Healthcare Market, Singapore
  • 3.8 Pharmaceutical Market - Major Players

4 Overview of Medical Devices Market

  • 4.1 Medical Device Market - Overview
  • 4.2 Medical Device Market - Major Segments
  • 4.3 Medical Device Market - Major Players

5 Pharmaceutical and Medical Device Market - Drivers and Barriers

  • 5.1 Drivers
  • 5.2 Barriers

6 Deal analysis

  • 6.1 Deal Analysis: M&A, VC, and PE Deals, Pharmaceutical Market, Singapore 2019-2020

7 HealthTech Landscape

  • 7.1 HealthTech Landscape
    • 7.1.1 HealthTech Deals Landscape, Singapore
  • 7.2 Key HealthTech Deals, Singapore
  • 7.3 Adoption of Technology in Healthcare, Singapore
  • 7.4 Key Developments: Technology in Healthcare, Singapore
  • 7.5 Regulatory Scenario Covering Use of Technology in Healthcare
  • 7.6 HealthTech Landscape- Singapore- Benefits and Risks

8 Market Access

  • 8.1 Overview of Healthcare System, Singapore
  • 8.2 Reimbursement of Medicinal Products, Singapore
  • 8.3 Overview of Public and Private Insurance Providers, Singapore
  • 8.4 Healthcare Spending and Health Price Index, Singapore
  • 8.5 Pricing Policies, Singapore
  • 8.3 Regulatory Landscape, Singapore
    • 8.3.1 Market Authorization for Pharmaceutical Drugs, Singapore
    • 8.3.2 Market Authorization for Medical Devices, Singapore
    • 8.3.3 Intellectual Property Rights, Patent, Singapore
    • 8.3.4 Intellectual Property Rights, Trademark, Singapore
    • 8.3.5 Pharmaceutical Clinical Trials Landscape, Singapore
    • 8.3.6 Clinical Trial Regulations, Singapore
    • 8.3.7 Exports and Imports Regulation, Singapore
    • 8.3.8 Pharmacy Regulation, Singapore
    • 8.3.9 Pharmaceutical Advertising Regulations, Singapore
    • 8.3.10 Labeling and Packaging Regulations, Singapore

9 Country Healthcare Landscape

  • 9.1 Singapore Healthcare Policy Highlights
  • 9.2 Healthcare Facilities, Singapore
  • 9.3 Healthcare Parameters, Singapore
  • 9.4 Life Expectancy and Immunization Rate, Singapore
  • 9.5 Environmental Health, Singapore
  • 9.6 Healthcare Personnel, Singapore
  • 9.7 Disease Burden, Singapore
  • 9.8 Healthcare Expenditure

10 Trade Associations, Singapore

11 Trade Fairs, Singapore

12 Opportunities and Challenges

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Coverage
    • 13.1.2 Secondary Research
    • 13.1.3 Forecasts
    • 13.1.4 Expert Panel
  • 13.2 Bibliography
  • 13.3 Contact Us
  • 13.4 Disclaimer

List of Tables

  • Table 1: Major Therapeutic Areas, Singapore, 2020
  • Table 2: COVID-19 Indicators (Number of cases), Global and Singapore, 2020
  • Table 3: COVID-19 Clinical Trials, Singapore, 2020
  • Table 4: COVID-19 Test Kits available for Diagnosis of COVID-19

List of Figures

  • Figure 1: Pharmaceutical Market, Singapore, Revenue ($B), 2012-2019
  • Figure 2: Medical Devices Market, Singapore, Revenue ($B), 2016-2019
  • Figure 3: Healthcare Startups in Singapore, Singapore, 2020
  • Figure 4: Number of Deals (2019-2020)
  • Figure 5: 2019-2020 Deal Overview by Region
  • Figure 6: Country Profile, Singapore, 2019
  • Figure 7: Pharmaceutical Market, Singapore, Revenue ($B), 2012-2019
  • Figure 8: Pharmaceutical Market, Singapore, Revenue Forecast ($B), 2020-2024
  • Figure 9: Pharmaceutical Market, Singapore, Pharmaceutical Exports ($B), 2012-2019
  • Figure 10: Pharmaceutical Market, Singapore, Top Export Partners, 2019
  • Figure 11: Pharmaceutical Market, Singapore, Pharmaceutical Imports, ($B), 2012-2019
  • Figure 12: Pharmaceutical Market, Singapore, Top Import Partners, 2019
  • Figure 13: Pharmaceutical Market, Supply Chain, Singapore, 2020
  • Figure 14: Growth of Biopharmaceutical Sector, Singapore, 2020
  • Figure 15: List of Registered Biosimilars, Singapore, 2009-2019
  • Figure 16: OTC Market, Singapore, Revenue ($B), 2012-2018
  • Figure 17: OTC Market by Drug Category, Singapore, Revenue ($M), 2018
  • Figure 18: Major Therapeutic Areas, Singapore, 2020
  • Figure 19: COVID-19 (Number of cases), Singapore, 2020
  • Figure 20: COVID-19 (Number of deaths), Singapore, 2020
  • Figure 21: Medical Devices Market, Singapore, Revenue ($B), 2016-2019
  • Figure 22: Medical Devices Market, Singapore, Revenue by Segment ($M), 2018
  • Figure 23: Medical Devices Market, Singapore, Revenue ($B) of Major Companies, 2019
  • Figure 24: Deal Value and Deal Count, Pharmaceutical Market, Singapore, 2019-2020
  • Figure 25: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Singapore, 2019
  • Figure 26: Deal Value and Deal Count Sub-types, Pharmaceutical Market, Singapore, 2019-2020
  • Figure 27: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Value ($M), 2019-2020
  • Figure 28: Pharmaceutical Market, Singapore, Venture Capital Financing Deals by Therapy Area, 2019-2020
  • Figure 29: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Number, 2019-2020
  • Figure 30: Medical Devices Market, Singapore, M&A Deals by Therapy Area, 2019-2020
  • Figure 31: Deal Value, HealthTech, Singapore, 2019-2020
  • Figure 32: Deal Count, HealthTech, Singapore, 2019-2020
  • Figure 33: Overview of Healthcare System, Singapore, 2020
  • Figure 34: MOH Organizational Structure, Singapore, 2020
  • Figure 35: Standard Drug List Formation, Singapore
  • Figure 36: Overview of Expedited Evaluation Process, Singapore, 2020
  • Figure 37: Overview of Full Evaluation Process, Singapore, 2020
  • Figure 38: Healthcare Financing, Singapore, 2020
  • Figure 39: Integrated Shield Plans (IPs), Singapore, 2020
  • Figure 40: OOP Expenditure (% of total expenditure on health), Singapore, 2012-2016
  • Figure 41: Annual Rate of Change (%), Health Price Index, Singapore, 2012-2019
  • Figure 42: HSA Organizational Structure, Singapore, 2020
  • Figure 43: Drug Registration Process, Singapore, 2020
  • Figure 44: Medical Devices Registration, Singapore, 2020
  • Figure 45: Patent Approval Process, Singapore, 2020
  • Figure 46: Trademark Approval Process, Singapore, 2020
  • Figure 47: Pharmaceutical Clinical Trials Count by Trial Status, Singapore, 2019-2020
  • Figure 48: Pharmaceutical Clinical Trials Count by Phase, Singapore, 2019-2020
  • Figure 49: Pharmaceutical Clinical Trials Count by Indication, Singapore, 2019-2020
  • Figure 50: Top Five Pharmaceutical Clinical Trials Sponsors by Count, Singapore, 2019-2020
  • Figure 51: CTA-CTN Regulatory Roadmap, Singapore, 2020
  • Figure 52: CTC Regulatory Roadmap, Singapore, 2020
  • Figure 53: Hospitals by Type (number), Singapore, 2012-2018
  • Figure 54: Hospitals (number), Singapore, 2012-2018
  • Figure 55: Acute Hospital Beds (number), Singapore, 2012-2018
  • Figure 56: Psychiatric Hospital Beds (number), Singapore, 2012-2018
  • Figure 57: Community Hospital Beds (number), Singapore, 2012-2018